# Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population

Study · id `cardio:ct-nct06096909` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06096909](<https://clinicaltrials.gov/study/NCT06096909>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06096909

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3684 participants.

## Technical summary

Registry record NCT06096909. Randomized; double masking; primary purpose treatment. Start 2023-11-11 (actual); primary completion 2028-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3684 participants (planned count; ClinicalTrials.gov record NCT06096909, source copy `cardio:ctgov-nct06096909-2026-10-27`, retrieved 2026-10-31)
- Started: 2023-11-11 (actual) (ClinicalTrials.gov record NCT06096909, source copy `cardio:ctgov-nct06096909-2026-10-27`, retrieved 2026-10-31)
- Primary completion: 2028-03-01 (anticipated) (ClinicalTrials.gov record NCT06096909, source copy `cardio:ctgov-nct06096909-2026-10-27`, retrieved 2026-10-31)
- Completion: 2028-06-01 (anticipated) (ClinicalTrials.gov record NCT06096909, source copy `cardio:ctgov-nct06096909-2026-10-27`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT06096909, source copy `cardio:ctgov-nct06096909-2026-10-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06096909-2026-10-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
- Condition: Acute Coronary Syndrome
- Condition: Non ST Segment Elevation Acute Coronary Syndrome
- Condition: Lipid Lowering, Vascular Inflammation
- Intervention (Drug): Tafolecimab
- Intervention (Drug): Cholesterol Absorption Inhibitor
- Intervention (Drug): Statin
- Lead sponsor: China National Center for Cardiovascular Diseases
- Lead sponsor class: OTHER\_GOV
- Collaborator: Innovent Biologics, Inc.
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry lists this organization as the lead sponsor: China National Center for Cardiovascular Diseases (`cardio:org-china-national-center-for-cardiovascular-diseases`)

## Provenance

Content hash: 201ba2b830857f5f1cc451f9c989efefdb5be1489667135249a3c334c884741c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
